The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s demonstrating significant promise in clinical trials for addressing obesity. Unlike some available weight loss treatments, retatrutide appears to deliver a significan